Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline) in Scleroderma: NCT06763783 Clinical Landscape Report 2026
16 October 2026
NCT06763783 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cladribine in Refractory acute myeloid leukemia: NCT06763666 Clinical Landscape Report 2026
16 October 2026
NCT06763666 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Venetoclax in Relapsing acute myeloid leukemia: NCT06763341 Clinical Landscape Report 2026
16 October 2026
NCT06763341 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Avapritinib in Acute Myeloid Leukemia: NCT06765915 Clinical Landscape Report 2026
16 October 2026
NCT06765915 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CART123 T Cells(Institute of Hematology and Blood Transfusion) in Acute Myeloid Leukemia: NCT06765876 Clinical Landscape Report 2026
16 October 2026
NCT06765876 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ziftomenib in Acute Myeloid Leukemia: NCT06769490 Clinical Landscape Report 2026
16 October 2026
NCT06769490 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Comekibart in Dermatitis, Atopic: NCT06765005 Clinical Landscape Report 2026
16 October 2026
NCT06765005 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Smoldering Multiple Myeloma: NCT06768489 Clinical Landscape Report 2026
16 October 2026
NCT06768489 clinical landscape for Smoldering Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Non-Muscle Invasive Bladder Urothelial Carcinoma: NCT06770582 Clinical Landscape Report 2026
16 October 2026
NCT06770582 clinical landscape for Non-Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Ruxolitinib Phosphate in Refractory acute myeloid leukemia: NCT06768476 Clinical Landscape Report 2026
16 October 2026
NCT06768476 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06770257 Clinical Landscape Report 2026
16 October 2026
NCT06770257 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tralokinumab in Dermatitis, Atopic: NCT06773455 Clinical Landscape Report 2026
16 October 2026
NCT06773455 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.